Navigation Links
Duska Therapeutics Obtains Standard & Poor's Listing
Date:6/26/2008

LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Duska Therapeutics is published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws. Standard Corporation Records is available in print, on CD-ROM, and via the Web at http://www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.

The Duska Therapeutics corporate information now available through the Records Listing Program includes an in-depth description of the Company's business operations, share price, dividend history, shares outstanding, company's financial position, earnings, and full income statement and balance sheet.

Earlier this month Duska Therapeutics announced it has been granted an exclusive worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. The lead candidate is expected to enter Phase II clinical trials later this year.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology company focused on the development of medical products based on adenosine triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, treatment of heart failure, treatment of chronic obstructive pulmonary disorder, and improvement of
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Attention To ,The Sneak Thief of Sight, NEW ... one of the,main causes of blindness around the globe, ... have announced the first annual,World Glaucoma Day, to be ... marked,by awareness and educational events organized by glaucoma institutions ...
... Inc.,(Nasdaq: HOLX ) today announced that Patrick Sullivan, ... presenting at the Merrill,Lynch Global Pharmaceutical, Biotechnology and Medical ... Hyatt Hotel in New York, NY., Interested parties ... of,Hologic,s investor presentation on Tuesday, February 5, 2008 at ...
... AlphaVax has,assembled its Cytomegalovirus (CMV) Advisory Board to provide ... candidates through clinical,development. To be chaired by Dr. Robert ... -- Mark Schleiss, MD, Professor, Associate Head ... Legion Chair in the Department of Pediatrics and Director, ...
Cached Biology Technology:World Glaucoma Day Set for March 6th 2Hologic to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2AlphaVax Announces New CMV Advisory Board 2
(Date:4/23/2014)... of asthma, allergies and other chronic inflammatory disorders among ... part to their reduced exposure to the microbes that ... paper. , The article, published in the journal ... in urban centers who have less access to green ... a condition caused by immune system dysfunction. , When ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... People who have had a stroke, often suffer motor ... a study conducted in Taiwan, that will be published ... but is currently freely available on-line as an unedited ... when one group of stroke victims had their own ... brain and a similar group did not, those who ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... Jobs, livelihoods and ecotourism industries can benefit from having ... coral reefs, marine researchers say. Despite their small ... often get more attention, herbivorous fish play a vital ... support the livelihoods of 500 million people worldwide, say ...
... 8th May 2012. A group of researchers from the ... INAD (Hospital del Mar Neuropsychiatry and Addictions Institute) has ... general overview at a chemical, pharmacological and behavioural level ... the Recreational Drugs European Network, as a new abused ...
... It is increasingly recognized that chronic psychotropic drug ... Indeed, clinical studies in humans present an intriguing picture: ... may contribute to cortical gray matter loss in patients, ... and mania, may preserve gray matter in patients. ...
Cached Biology News:Weed-eating fish 'help protect jobs, livelihoods' 2Weed-eating fish 'help protect jobs, livelihoods' 3Internet and new drugs: A challenge for public health 2Psychiatric medication effects on brain structure 2
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
5 minutes from gel band to purified DNA...
... commonly used in baculovirus plaque ... agaroses either contain contaminants that ... or lack the physical characteristics ... Novagen's BacPlaque Agarose is pre-qualified ...
...
Biology Products: